Severe Myocarditis after Nivolumab and Ipilimumab in a Patient with Microsatellite Instability-High Gastric Adenocarcinoma: A Case Report
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Myocarditis attributable to immune checkpoint inhibitors is regarded as among the most serious complications of immunotherapeutic treatment. We report a case of gastric cancer who developed myocarditis, and subsequent late complications following treatment with nivolumab and ipilimumab. The patient was managed with corticosteroids, mycophenolate mofetil (MMF), and intravenous immunoglobulin G (IVIG), but later developed supraventricular tachycardia and deep vein thrombosis. This report emphasizes the need to enhance recognition of immune-related toxicities within non-oncology specialties to support prompt interdisciplinary collaboration and appropriate patient management. Additionally, patients can develop myocarditis-related complications even when clinically stable or near the end of treatment, underscoring the need for close and ongoing monitoring.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Viral Infections and Immunology Research
Chemotherapy-induced cardiotoxicity and mitigation
Publication details
- Journal / source
- Nigerian Journal of Clinical Practice
- Volume
- 29
- Issue
- 3
- Pages
- 356–359
- Publication date
- 1 March 2026
- Language
- EN